A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)
Vascular Health and Risk Management
Percutaneous coronary revascularization has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, fi rst-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher ® ) and paclitaxel-eluting stents (Taxus ® ), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. There is currently debate on the safety of these fidoi:10.2147/vhrm.s1838 fatcat:4bnz56mbpjbtfg3fz42cwa6foq